ASH 2018 | Ibrutinib-obinutuzumab produces superior results in the frontline for CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
More exciting results with ibrutinib for chronic lymphocytic leukemia (CLL) were unveiled at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Here, Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, presents the exciting results of the Phase III iLLUMINATE study (NCT02264574), which investigated ibrutinib-obinutuzumab vs. chlorambucil-obinutuzumab as a first-line treatment for CLL. This therapy resulted in superior progression-free survival, regardless of high-risk genomic features, as well as higher response rates and depth of remission (in terms of complete response and undetectable MRD). Dr Flinn also highlights pertinent questions in the field, including which of the many doublets under investigation are best, the optimal sequence of therapy and treatment cessation.
Get great new content delivered to your inboxSign up